Two RNAi Rx Shops See Strong Gains in Share Value Since the Start of Year

Since the start of the year, MDRNA and Tekmira Pharmaceuticals have been significantly outperforming the bellwether Nasdaq Biotechnology Index, while Alnylam and RXi have lost ground.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.